Identify
Ideal for patients with diabetes, hypertension, high cholesterol or obesity — those who benefit most from early cardiovascular insight.
AI cardiovascular risk · distributed by CityMedicYour eyes reveal your heart.
Dr.Noon by Mediwhale assesses cardiovascular disease risk from a single photo of the retina. In peer-reviewed studies its retinal biomarker predicted risk with performance comparable to a coronary-artery calcium (CT) score — yet it's non-invasive, radiation-free, and takes under three minutes.
Under 3 minutes No radiation Runs in primary care
Distributed by CityMedic — across Malaysia's leading hospitals & health systems
Why the retina
The one place a doctor can see your blood vessels directly.
The retina is the only part of the body where the microvasculature can be observed in vivo, without surgery. Dr.Noon's deep-learning biomarker — Reti-CVD — reads subtle patterns in those vessels from a standard fundus photograph to estimate future cardiovascular risk, a non-invasive complement to blood panels and cardiac imaging.
How Dr.Noon works
A simple, five-step clinical workflow that fits an everyday consultation.
Capture
A trained operator takes a quick retinal (fundus) photo of each eye — non-invasive, no needles, no radiation.
Analyse
Images are processed by Dr.Noon's deep-learning retinal biomarker (Reti-CVD), on a secure cloud or in-house server.
Report
An automated cardiovascular-risk report is generated for the clinician within minutes.
Act
Clinicians use the result to guide prevention, lifestyle advice, and onward referral.
Clear, clinician-ready reports
Every scan produces an easy-to-read report — a cardiovascular risk status, a plain-language explanation, and recommendations — that you and your patient can act on together in the same visit.
- A clear risk status at a glance
- Plain-language explanation and next steps
- Eye and heart views in one report
Compared with traditional screening
Dr.Noon isn't a replacement for every test — it's an accessible, non-invasive way to surface cardiovascular risk earlier, in settings that don't have a CT scanner.
| Dr.Noon (retinal AI) | Coronary CT (CACS) | Standard risk score | |
|---|---|---|---|
| Invasiveness | None (retinal photo) | Imaging + sometimes contrast | Blood draw |
| Radiation | None | Yes (CT) | None |
| Time to result | Under 3 minutes | Same/next day | Lab turnaround |
| Where it can run | Primary care & clinics | Imaging centres | Most settings |
| Relative cost | Low | High | Low–moderate |
Why clinicians choose Dr.Noon
Non-invasive & radiation-free
No blood draw, no contrast, no radiation — just a photograph of the eye.
Fast
A cardiovascular-risk read in under three minutes, with no waiting for lab work.
Accessible
Runs from a standard fundus camera, so it fits primary care, clinics and screening centres — not just tertiary hospitals.
Cost-effective
A lower-cost way to surface cardiovascular risk earlier, complementing existing tools.
Clinically validated
Backed by peer-reviewed research and pivotal-trial data (see below).
Regulatory-cleared
CE-marked and approved by Korea's MFDS, with reimbursement secured there (per Mediwhale).
The evidence
Mediwhale reports more than 50 peer-reviewed publications behind Dr.Noon, alongside recognition including a CES 2023 Innovation Award and top honours at MICCAI 2024. A selection of the research:
Recognition
Add cardiovascular insight to your screening — from a photograph.
CityMedic distributes Dr.Noon by Mediwhale in Malaysia. Talk to us about a demo or bringing it to your clinic, hospital, or screening programme.
For professional use. Dr.Noon is a cardiovascular risk-assessment aid, not a diagnosis, and is intended to support — not replace — clinical judgement. Regulatory status varies by market; figures and approvals cited are as reported by the manufacturer, Mediwhale.